A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS)

被引:0
|
作者
Yao, Wanru [1 ]
Ai, Di [1 ]
Zhang, Qing [2 ]
Li, Xiaojing [3 ]
Zhou, Min [2 ]
Zhang, Ningning [4 ]
Yang, Sheng [5 ]
Chen, Zhenping [6 ]
Zhen, Yingzi [1 ]
Luke, Koon-Hung [7 ,8 ]
Wu, Runhui [1 ,9 ]
机构
[1] Capital Med Univ, Key Lab Major Dis Children,Minist Educ,Beijing Chi, Natl Ctr Childrens Hlth,Natl Key Discipline Pediat, Hematol Dept,Beijing Key Lab Pediat Hematol Oncol, Beijing, Peoples R China
[2] Univ Elect Sci & Technol China, Chengdu Womens & Childrens Cent Hosp, Sch Med, Haemophilia Diag & Treatment Ctr,Dept Hematol & On, Chengdu, Peoples R China
[3] New Century Womens & Childrens Hosp, Dept Pediat, Hemophilia Treatment Ctr, Chengdu, Peoples R China
[4] Capital Med Univ, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Dept Radiol, Beijing, Peoples R China
[5] Univ Elect Sci & Technol China, Chengdu Womens & Childrens Cent Hosp, Sch Med, Dept Ultrasound, Chengdu, Peoples R China
[6] Capital Med Univ, Beijing Childrens Hosp, Beijing Pediat Res Inst, Hematol Dis Lab, Beijing, Peoples R China
[7] Univ Ottawa, Children Hosp Eastern Ontario, Div Hematol & Oncol, Dept Pediat,Lab Med & Pathol, Ottawa, ON, Canada
[8] Univ Ottawa, Childrens Hosp Eastern Ontario CHEO, Dept Pediat, Div Hematol & Oncol, Ottawa, ON, Canada
[9] Capital Med Univ, Beijing Childrens Hosp, Hematol Ctr, Natl Ctr Childrens Hlth, Beijing 100045, Peoples R China
关键词
Haemophilia A; Individualized prophylaxis; Bleeding; China; Haemarthrosis; ARTHROPATHY; CHILDREN; LIFE;
D O I
10.1016/j.thromres.2024.109110
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The Chinese Haemophilia Individualized Prophylaxis Study (CHIPS), which was launched in 2016, reported a significant reduction in haemarthrosis over a one-year study. However, its long-term efficacy requires verification. This paper summarizes the clinical outcomes of 18 severe haemophilia A (SHA) patients who completed one year on the CHIPS and 3 more years of follow-up.<br /> Methods: Clinical follow-up was based on the CHIPS protocol (from July 2018 to July 2021). Escalation was based on index joint bleeding, and serial ultrasound (greyscale and colour Doppler) examinations of the index joints (both sides of the ankles, knees and elbows) were conducted every 6 months via a scoring system.<br /> Results: A total of 18 SHA patients completed the 3-year study. Fifteen patients dropped out due to the financial crisis during the COVID-19 pandemic in China. The median age was 5.4 (range 4.3-6.9) years. A significant reduction in haemarthrosis was achieved, with mean annual bleeding rates reduced from 18.9 f 2.8 to 1.7 f 0.4 (p < 0.001), annual joint bleeding rates from 3.1 f 0.7 to1.2 f 0.3 (p < 0.028). 5 out of 8 target joint resolved. Sixteen doses were escalated. At study exit, the heterogeneous treatment outcomes of the SHA boys were 5 at step 4 (20-25 lU/kg, every other day), 10 at step 3 (15-20 IU/kg, 3x/week), 2 at step 2 (10-15 lU/kg, 3x/week) and 1 at step 1 (10-15 lU/kg, 2x/week). The mean FVIII consumption was 2964 IU/kg/year, with savings. The quality of life improved, with Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT, Chinese Version 2.0) scores ranging from 68.8 to 78.8. There was no change in the ultrasound score.<br /> Conclusion: Our follow-up data on the 18 SHA boys after completing one year on the CHIPS verify the long-term efficacy of the CHIPS for haemarthrosis reduction, joint health preservation, improvement in the quality of life of the boys and cost savings.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] IMPROVEMENT IN PAIN-RELATED QUALITY OF LIFE IN PATIENTS WITH HAEMOPHILIA A TREATED WITH RFVIIIFC INDIVIDUALIZED PROPHYLAXIS: POST-HOC ANALYSIS FROM A- LONG
    Pasi, J.
    Hermans, C.
    Hakimi, Z.
    Nazir, J.
    DasMahapatra, P.
    Aballea, S.
    Ezzalfani, M.
    Fatoye, F. A.
    HAEMOPHILIA, 2021, 27 : 89 - 90
  • [42] Effect of low-dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A
    Gamal Andrawes, Nevine
    Hashem Fayek, Manal
    Salah El-Din, Nouran
    Atef Mostafa, Raguia
    HAEMOPHILIA, 2020, 26 (02) : 325 - 332
  • [43] Exploring baseline characteristics, treatment decisions and patient-centred outcomes of people with severe haemophilia A receiving prophylaxis: Early findings from the multi-country 'Cost of Haemophilia: A Socioeconomic Survey III' (CHESS III) study
    Chowdary, Pratima
    Polito, Letizia
    Chafaie, Romain
    Moreno, Katya
    Blenkiron, Tom
    Burke, Tom
    Grazzi, Enrico Ferri
    HAEMOPHILIA, 2024, 30 : 165 - 167
  • [44] REAL-WORLD OUTCOMES IN PATIENTS WITH HAE RECEIVING LANADELUMAB LONG-TERM PROPHYLAXIS FOR 3 YEARS OR LONGER
    Lumry, W.
    Davis-Lorton, M.
    Soteres, D.
    Earl, L.
    Wynne-Cattanach, K.
    Sing, K.
    Juethner, S.
    Schultz, B.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S29 - S29
  • [45] Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ≥40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
    Reding, Mark T.
    Pabinger, Ingrid
    Holme, Pal Andre
    Maas Enriquez, Monika
    Mancuso, Maria Elisa
    Lalezari, Shadan
    Miesbach, Wolfgang
    Di Minno, Giovanni
    Klamroth, Robert
    Hermans, Cedric
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2023, 14
  • [46] Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children
    Chozie, Novie A.
    Primacakti, Fitri
    Gatot, Djajadiman
    Setiabudhy, Rahajuningsih D.
    Tulaar, Angela B. M.
    Prasetyo, Marcel
    HAEMOPHILIA, 2019, 25 (04) : 633 - 639
  • [47] Long-Term Efficacy of Recombinant Factor VIII FC Fusion Protein (rFVIIIFC) Prophylaxis in Paediatric, Adolescent, and Adult Subjects with Target Joints and Severe Haemophilia A
    Pasi, K. J.
    Pabinger, I.
    Kerlin, B. A.
    Kulkarni, R.
    Nolan, B.
    Wang, M.
    Liesner, R.
    Brown, S. A.
    Hanabusa, H.
    Tsao, E.
    Allen, G.
    HAEMOPHILIA, 2016, 22 : 21 - 21
  • [48] Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial
    Lentz, Steven R.
    Janic, Dragana
    Kavakli, Kaan
    Miljic, Predrag
    Oldenburg, Johannes
    Ozelo, Margareth C.
    Santagostino, Elena
    Suzuki, Takashi
    Salek, Silva Zupancic
    Korsholm, Lars
    Matytsina, Irina
    Tiede, Andreas
    HAEMOPHILIA, 2018, 24 (06) : E391 - E394
  • [49] Long-term efficacy and safety of damoctocog alfa pegol prophylaxis in patients with haemophilia A aged 12-&lt;18 years at enrolment into PROTECT VIII
    Reding, Mark T.
    Simpson, Mindy
    Ducore, Jonathan
    Holme, Pal Andre
    Enriquez, Monika Maas
    Mancuso, Maria Elisa
    ACTA HAEMATOLOGICA, 2024,
  • [50] Effectiveness of monthly low dose emicizumab prophylaxis without 4-week loading doses among patients with haemophilia A with and without inhibitors: A case series report
    Chuansumrit, Ampaiwan
    Sirachainan, Nongnuch
    Jaovisidha, Suphaneewan
    Jiravichitchai, Tachit
    Kadegasem, Praguywan
    Kempka, Ketsuda
    Panuwannakorn, Monratta
    Rotchanapanya, Wannaphorn
    Nuntiyakul, Thunyakorn
    HAEMOPHILIA, 2023, 29 (01) : 382 - 385